“VENETOCLAX - Emerging Insight and Market Forecast - 2030” the report provides comprehensive insights about an investigational product for Follicular lymphoma in 7 Major Markets. A detailed picture of the VENETOCLAX in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020 - 2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.
Overview VENETOCLAX is a first-in-class targeted medicine designed to selectively bind and inhibit the B-cell lymphoma-2 (BCL-2) protein. In some blood cancers and other tumors, BCL-2 builds up and prevents cancer cells from dying or self-destructing, a process called apoptosis. Venetoclax blocks the BCL-2 protein and works to restore the process of apoptosis. Venetoclax is being developed by AbbVie and Genentech, a member of the Roche Group. It is currently in Phase II for Follicular lymphoma.
Scope of the report The report provides insights into:
• A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
• Elaborated details on regulatory milestones and other development activities have been provided in this report.
• The report also highlights the drug research and development activity details across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around VENETOCLAX.
• The report contains forecasted sales for VENETOCLAX till 2030.
• Comprehensive coverage of the late-stage emerging therapies (Phase III) for Follicular lymphoma.
• The report also features the SWOT analysis with analyst insights and key findings of VENETOCLAX.
Methodology The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
VENETOCLAX Analytical Perspective • In-depth VENETOCLAX Market Assessment
This report provides a detailed market assessment of VENETOCLAX in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.
• VENETOCLAX Clinical Assessment
The report provides the clinical trials information of VENETOCLAX covering trial interventions, trial conditions, trial status, start and completion dates.
Report highlights • In the coming years, the market scenario for Follicular lymphoma is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence VENETOCLAX dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Other emerging products for Follicular lymphoma are giving market competition to VENETOCLAX and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of VENETOCLAX.
• Our in-depth analysis of the forecasted sales data of VENETOCLAX from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the VENETOCLAX.
Key Questions • Which company is developing VENETOCLAX along with the phase of the clinical study?
• What is the technology utilized in the development of VENETOCLAX?
• What is the product type, route of administration and mechanism of action of VENETOCLAX?
• What is the clinical trial status of the study and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the VENETOCLAX development?
• What are the key designations that have been granted to VENETOCLAX?
• What is the forecasted market scenario of VENETOCLAX?
• What is the history of VENETOCLAX and what is its future?
• What is the forecasted sales of VENETOCLAX in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how these are giving competition to VENETOCLAX?
• Which are the late-stage emerging therapies under development for the treatment of the Follicular Lymphoma?
Our reports have been used by over 10K customers, including:
The global recombinant proteins market is projected to reach USD 1.7billion by 2026 from USD 1.0billion in 2021, at a CAGR of 9.8% during the forecast period. The market growth is primarily driven by factors such as increasing government investments and R&D expenditure in pharmaceutical & biotechnology companies, growing industryacademia collaborations,...
206 pages •
By The Business Research Company
• Dec 2020
Pegfilgrastim Biosimilars Global Market Opportunities And Strategies To 2030: COVID 19 Impact And Recovery provides the strategists, marketers and senior management with the critical information they need to assess the global pegfilgrastim biosimilars market. Description: Where is the largest and fastest growing...
The global cell isolation market size is projected to reach USD 15.0 billion by 2025 from USD 6.9billion in 2020, at a CAGR of 16.8% during the forecast period. Market growth is driven by factors The growing investments in personalized medicine can primarily be attributed to the growing demand for advanced treatments with minimal side-effects...
200 pages •
By The Business Research Company
• Dec 2020
Major players in the enzymes market are Sanofi, AbbVie Inc., Alexion Pharmaceuticals Inc, Horizon Pharma, Allergan plc, Pfizer Inc., Vivus, Digestive Care, Leadiant Biosciences and Roche Holdings AG. The global enzymes market is expected to decline from $7.98 billion in 2019 to $7.81 billion in 2020 at a compound annual growth rate...
“Venetoclax - Emerging Insight and Market Forecast - 2030” the report provides comprehensive insights about an investigational product for Diabetic Macular Edema in 7 Major Markets. A detailed picture of the Venetoclax in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the...
‘Paroxysmal nocturnal hemoglobinuria (PNH) – Epidemiology Forecast—2030’ report delivers an in-depth understanding of the historical and forecasted epidemiology of PNH in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Paroxysmal nocturnal hemoglobinuria (PNH): Disease Understanding PNH...
The protein A resin market is expected to reach USD 1.9 billion by 2025 from USD 1.1 billion in 2020, at a CAGR of 11.4% during the forecast period. The protein A resin market has witnessed increasing consumption due to increased monoclonal antibody production on account of the pandemic situation worldwide.. Growth in the market can primarily...
The fill finish manufacturing market was valued at US$ 6,129.03 million in 2019 and is projected to reach US$ 12,547.23 million by 2027; it is expected to grow at a CAGR of 9.6% from 2020 to 2027. The growth of the fill finish manufacturing market is mainly attributed to factors such as rising adoption of prefilled syringes for parenteral...
‘Paroxysmal nocturnal hemoglobinuria (PNH)– Market Insights, Epidemiology, and Market Forecast—2030’ report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of PNH in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The PNH market report provides...
The anti-money laundering solution market was valued at US$ 1,503.99 million in 2019 and is projected to reach US$ 5,866.51 million by 2027; it is expected to grow at a CAGR of 16.2% from 2020 to 2027. Transaction monitoring is a crucial procedure and key control in anti-money laundering (AML) and countering the financing of terrorism (AML/CFT)...
Research And Development
Cause-Specific Mortality Rate
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.